Neonc Technologies Holdings Inc (NTHI)

$12.00 -0.11 (-0.91%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 9,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, h...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 663 7831
Address:
23975 Park Sorrento, Suite 205, Calabasas, United States
focafoca99
focafoca99 Apr. 25 at 5:58 AM
$NTHI completed an additional closing under its securities purchase agreement.
0 · Reply
notreload_ai
notreload_ai Apr. 24 at 1:53 PM
$AAPG $NTHI $RKT $SHAK $LIDR -- THE WSJ
0 · Reply
DARKP00L
DARKP00L Apr. 24 at 11:17 AM
$NTHI 07:16 on Apr. 24 2026 BTIG Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $15 #tradeideas
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 23 at 2:57 AM
$NTHI NeOnc Technologies recently announced approximately $300,000 in open-market stock purchases by Chairman & CEO Amir Heshmatpour, reinforcing management’s alignment with shareholders and confidence in the Company’s long-term strategy. These purchases come ahead of several anticipated near-term milestones: • NEO100 - interim clinical data readout expected within ~4 months • NEO212 - expected FDA Type B End-of-Phase meeting to align on a potential registrational Phase 2 pathway within ~4 weeks NeOnc continues advancing its multi-program pipeline targeting central nervous system cancers, with a focus on therapies designed to overcome the challenges of the blood-brain barrier. Read the full announcement here: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-holdings-inc-announces-300000-insider
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 19 at 9:54 AM
$NTHI ICYMI, Watch on YouTube: NeOnc Technologies | One Year on NASDAQ (NTHI) | Progress, Pipeline & What’s Next One year after NeOnc Technologies' listing on NASDAQ under the ticker NTHI, NeOnc reflects on key clinical and regulatory milestones achieved as a public company. This video highlights progress across the pipeline, reinforces the company’s strategic positioning, and looks ahead to the next phase of execution, bringing innovative therapies closer to patients who need them most. https://www.youtube.com/watch?v=uxcjTkb2xT8
0 · Reply
Dcvfin
Dcvfin Apr. 19 at 12:56 AM
$NTHI in reading their press releases and 2025 annual report, I’ve found several obvious typos and errors Seems like a red flag to me
0 · Reply
Abdul92z
Abdul92z Apr. 17 at 2:38 PM
Watching $SRFM $NTHI $NIVF
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 16 at 2:02 AM
$NTHI Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented on the recent Business Update and Q4 2025 Financial Report: “Q4 2025 and early 2026 marked important inflection points for NeOnc. We completed NEO212’s Phase 1 dose escalation and established a recommended Phase 2 dose of 610 mg, with early signs of possible anti-tumor activity in heavily pretreated patients. In parallel, the NEO100 Phase 2a study in recurrent IDH1-mutant high-grade glioma is fully enrolled. Updated Phase 1/2a data suggested a 24% radiographic remission rate, 44% six-month progression-free survival, and no significant toxicity.”
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 15 at 7:00 AM
$NTHI NeOnc Technologies recently reported Q4 2025 results and highlights of clinical and strategic progress. Key announcements include: NEO212 Phase 1 completed; RP2D set at 610 mg with FDA End-of-Phase 1 meeting planned and registrational Phase 2 pathway under evaluation NEO100 Phase 2a fully enrolled; interim readout expected ~August 2026 Expanded NEO100 dataset (n=25): 24% remission vs. ~8% historical benchmark; 44% six-month PFS; 36% survival ≥18 months $10M PIPE commitment strengthens balance sheet to support clinical execution Leadership strengthened with new CEO, CAO, and two leading neuro-oncologists joining the Scientific Advisory Board Continued visibility across Bloomberg Television and Fox Business Q4 2025 investment: R&D $3.6M; G&A $4.8M supporting pipeline advancement and partnerships. These updates reflect continued execution across clinical development, leadership expansion, and strategic positioning heading into the next phase of growth. Read more here: https://investors.neonc.com/news-releases/news-release-details/neonc-provides-business-update-and-reports-q4-2025-financial
0 · Reply
focafoca99
focafoca99 Apr. 11 at 9:10 PM
$NTHI launched a new ATM program that can sell up to $75 million of common stock through BTIG and Alliance Global Partners.
0 · Reply
Latest News on NTHI
NeOnc Provides Business Update and Reports Q4 2025 Financial Results

Apr 1, 2026, 9:00 AM EDT - 24 days ago

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Mar 13, 2026, 9:00 AM EDT - 6 weeks ago

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Mar 12, 2026, 8:52 AM EDT - 6 weeks ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

Mar 4, 2026, 8:00 AM EST - 7 weeks ago

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

MRK

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

Feb 27, 2026, 9:00 AM EST - 2 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Jan 30, 2026, 9:00 AM EST - 3 months ago

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Jan 9, 2026, 7:32 PM EST - 3 months ago

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Reports Updated Clinical Results

Dec 15, 2025, 9:00 AM EST - 4 months ago

NeOnc Technologies Reports Updated Clinical Results

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

Dec 1, 2025, 9:00 AM EST - 5 months ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

Nov 13, 2025, 9:00 AM EST - 5 months ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

Nov 7, 2025, 9:00 AM EST - 6 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Oct 9, 2025, 9:00 AM EDT - 7 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 29, 2025, 9:00 AM EDT - 7 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

Sep 10, 2025, 9:40 AM EDT - 8 months ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Sep 10, 2025, 9:00 AM EDT - 8 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 25, 2025, 9:00 AM EDT - 8 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 11, 2025, 9:00 AM EDT - 9 months ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 7, 2025, 9:00 AM EDT - 9 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Aug 4, 2025, 9:00 AM EDT - 9 months ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 30, 2025, 9:00 AM EDT - 9 months ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 23, 2025, 10:53 AM EDT - 9 months ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

Jul 8, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Jun 6, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Apr 15, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

Apr 14, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Apr 10, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Apr 8, 2025, 4:05 PM EDT - 1 year ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Mar 31, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 27, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:45 AM EDT - 1 year ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 1 year ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Oct 7, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Aug 5, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jul 16, 2024, 11:15 AM EDT - 1 year ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Jun 26, 2024, 4:39 PM EDT - 1 year ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

May 15, 2024, 11:00 AM EDT - 2 years ago

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

May 9, 2024, 5:30 PM EDT - 2 years ago

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

focafoca99
focafoca99 Apr. 25 at 5:58 AM
$NTHI completed an additional closing under its securities purchase agreement.
0 · Reply
notreload_ai
notreload_ai Apr. 24 at 1:53 PM
$AAPG $NTHI $RKT $SHAK $LIDR -- THE WSJ
0 · Reply
DARKP00L
DARKP00L Apr. 24 at 11:17 AM
$NTHI 07:16 on Apr. 24 2026 BTIG Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $15 #tradeideas
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 23 at 2:57 AM
$NTHI NeOnc Technologies recently announced approximately $300,000 in open-market stock purchases by Chairman & CEO Amir Heshmatpour, reinforcing management’s alignment with shareholders and confidence in the Company’s long-term strategy. These purchases come ahead of several anticipated near-term milestones: • NEO100 - interim clinical data readout expected within ~4 months • NEO212 - expected FDA Type B End-of-Phase meeting to align on a potential registrational Phase 2 pathway within ~4 weeks NeOnc continues advancing its multi-program pipeline targeting central nervous system cancers, with a focus on therapies designed to overcome the challenges of the blood-brain barrier. Read the full announcement here: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-holdings-inc-announces-300000-insider
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 19 at 9:54 AM
$NTHI ICYMI, Watch on YouTube: NeOnc Technologies | One Year on NASDAQ (NTHI) | Progress, Pipeline & What’s Next One year after NeOnc Technologies' listing on NASDAQ under the ticker NTHI, NeOnc reflects on key clinical and regulatory milestones achieved as a public company. This video highlights progress across the pipeline, reinforces the company’s strategic positioning, and looks ahead to the next phase of execution, bringing innovative therapies closer to patients who need them most. https://www.youtube.com/watch?v=uxcjTkb2xT8
0 · Reply
Dcvfin
Dcvfin Apr. 19 at 12:56 AM
$NTHI in reading their press releases and 2025 annual report, I’ve found several obvious typos and errors Seems like a red flag to me
0 · Reply
Abdul92z
Abdul92z Apr. 17 at 2:38 PM
Watching $SRFM $NTHI $NIVF
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 16 at 2:02 AM
$NTHI Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented on the recent Business Update and Q4 2025 Financial Report: “Q4 2025 and early 2026 marked important inflection points for NeOnc. We completed NEO212’s Phase 1 dose escalation and established a recommended Phase 2 dose of 610 mg, with early signs of possible anti-tumor activity in heavily pretreated patients. In parallel, the NEO100 Phase 2a study in recurrent IDH1-mutant high-grade glioma is fully enrolled. Updated Phase 1/2a data suggested a 24% radiographic remission rate, 44% six-month progression-free survival, and no significant toxicity.”
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 15 at 7:00 AM
$NTHI NeOnc Technologies recently reported Q4 2025 results and highlights of clinical and strategic progress. Key announcements include: NEO212 Phase 1 completed; RP2D set at 610 mg with FDA End-of-Phase 1 meeting planned and registrational Phase 2 pathway under evaluation NEO100 Phase 2a fully enrolled; interim readout expected ~August 2026 Expanded NEO100 dataset (n=25): 24% remission vs. ~8% historical benchmark; 44% six-month PFS; 36% survival ≥18 months $10M PIPE commitment strengthens balance sheet to support clinical execution Leadership strengthened with new CEO, CAO, and two leading neuro-oncologists joining the Scientific Advisory Board Continued visibility across Bloomberg Television and Fox Business Q4 2025 investment: R&D $3.6M; G&A $4.8M supporting pipeline advancement and partnerships. These updates reflect continued execution across clinical development, leadership expansion, and strategic positioning heading into the next phase of growth. Read more here: https://investors.neonc.com/news-releases/news-release-details/neonc-provides-business-update-and-reports-q4-2025-financial
0 · Reply
focafoca99
focafoca99 Apr. 11 at 9:10 PM
$NTHI launched a new ATM program that can sell up to $75 million of common stock through BTIG and Alliance Global Partners.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 9 at 2:49 AM
$NTHI The Q4 2025 results reflect continued investment in advancing NEO100 and NEO212 through development. The reported net loss includes approximately $40M in non-cash impact, primarily from stock-based compensation. This reflects a deliberate decision to align leadership and scientific advisors with long-term outcomes while preserving cash to support clinical execution. As a result, the headline figure does not reflect operating cash usage. On a cash basis, the underlying burn is materially lower and consistent with a clinical-stage biotech advancing multiple programs. Execution remains the priority as development progresses across the pipeline.
0 · Reply
FilingTracker
FilingTracker Apr. 7 at 12:57 AM
$NTHI Insider purchase by President: https://www.sec.gov/Archives/edgar/data/1443035/000121390026040635/xslF345X06/marketforms-72891.xml
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 6 at 3:30 AM
$NTHI Top Entrepreneurs Going into 2026 via @USATODAY We’re thrilled to celebrate our CEO, Amir Heshmatpour, being featured in USA Today’s list of Top Entrepreneurs Going Into 2026, a testament to visionary leadership and bold innovation shaping the future of biotech. Congratulations to Amir & NeOnc! Here’s to a year of breakthrough science, meaningful progress, and continued impact for patients worldwide. #Leadership #Entrepreneurship #Biotech #Innovation #2026Vision https://www.usatoday.com/story/special/contributor-content/2026/02/23/top-entrepreneurs-going-into-2026/88825698007/
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 4 at 4:37 PM
$NTHI Driving Scientific Innovation into Commercial Impact NeOnc Technologies leverages a robust ecosystem of research, regulatory, and management expertise to accelerate the translation of cutting-edge science from the lab to the clinic and into the marketplace. Watch our full conversation with New To The Street TV here: https://bit.ly/NTTS-NeOncBreaksThroughBrainCancerTreatment #NeOncTechnologies #Quazar #BiotechInnovation #InvestorRelations #MarketImpact
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 2 at 6:10 PM
$NTHI NeOnc Technologies | One Year on NASDAQ (NTHI) | Progress, Pipeline & What’s Next One year after NeOnc Technologies' listing on NASDAQ under the ticker NTHI, NeOnc reflects on key clinical and regulatory milestones achieved as a public company. This video highlights progress across the pipeline, reinforces the company’s strategic positioning, and looks ahead to the next phase of execution, bringing innovative therapies closer to patients who need them most. https://www.youtube.com/watch?v=uxcjTkb2xT8
0 · Reply
focafoca99
focafoca99 Apr. 1 at 7:22 PM
$NTHI packed a lot into this update: NEO212 finished Phase 1, NEO100 Phase 2a is fully enrolled, and the balance sheet got help from a $10 million PIPE anchor.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 29 at 6:38 AM
$NTHI At NeOnc Technologies, we are focused on addressing one of the greatest challenges in modern medicine: effectively treating diseases of the brain. Our work centers on overcoming the blood-brain barrier through innovative delivery approaches, including intranasal therapies designed to transport treatment directly to the brain. With clinical-stage programs such as NEO100 and NEO212, we are advancing new possibilities for patients facing aggressive conditions like glioblastoma. The global need for effective CNS therapies continues to grow, representing a significant and largely unmet market opportunity across oncology and neurology. We remain committed to advancing our pipeline and delivering meaningful impact for patients, partners, and shareholders.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 25 at 9:32 AM
$NTHI A quote from NeOnc Technologies founder, Dr. Thomas Chen, Chief Medical Officer: “The determination of the RP2D at 610 mg is a scientifically significant achievement. It confirms that our bio-conjugation technology allows for high-dose delivery of therapeutic agents with a manageable toxicity profile. We are now positioned to explore the efficacy of this optimized dose in our upcoming Phase 2 expansion.”
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 24 at 11:19 AM
$NTHI 📢 Leadership Update at NeOnc Technologies Holdings Inc NTHI NeOnc announces the appointment of David Choi as Chief Accounting Officer, strengthening the Company’s financial leadership as it advances its clinical programs targeting central nervous system (CNS) cancers. With more than a decade of experience in technical accounting, SEC reporting, and internal controls, David has held leadership roles at Blythe Global Advisors, Grant Thornton, and Ernst & Young, advising public and private companies on complex financial and compliance matters. As NeOnc continues progressing its clinical-stage biotechnology platform and expanding global operations, David will oversee accounting, financial reporting, internal controls, and corporate governance to support the Company’s continued growth. Welcome to the team, David. Read the full press release: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-appoints-david-choi-chief-accounting-officer
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 23 at 11:06 PM
$NTHI
0 · Reply
joe_blough
joe_blough Mar. 23 at 12:55 PM
$NTHI I checked the news & found nothing negative to cause its recent dive, so I checked fintel for short interest, which hasn't changed, except for that going into Dark Pool $$, which I don't time to check but is at 48%. Also shares available to be shorted has increased from 35k to 400k, so I guess it's all going into the Dark Pool. Somebody apparently is trying for a big chunk of this, at a cheap price. It's a shame this behavior is allowed
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 18 at 9:01 AM
$NTHI Amir Heshmatpour, Chairman and CEO of NTHI, on the recently announced data from the dose-escalation portion of our Phase 1/2 clinical trial for NEO212: ”These early efficacy signals, observed even within a dose-escalation safety study, provide meaningful clinical validation of NEO212’s therapeutic potential. With RP2D now established, we believe NeOnc is entering Phase 2 with positive clinical momentum and a clear development pathway.” Read more about this exciting news here: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-reports-phase-1-dose-escalation-results
0 · Reply